Doxylamine succinate: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 110: Line 110:
* Sleeplessness persists continuously for more than two weeks. Insomnia may be a symptom of serious underlying medical illness.
* Sleeplessness persists continuously for more than two weeks. Insomnia may be a symptom of serious underlying medical illness.


* If pregnant or breast-feeding,
'''If pregnant or breast-feeding''',


'''Ask a health professional before use'''
* Ask a health professional before use'''


'''Keep out of reach of children'''
'''Keep out of reach of children'''

Revision as of 16:39, 7 January 2015

Doxylamine succinate
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Kiran Singh, M.D. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Doxylamine succinate is a {{{drugClass}}} that is FDA approved for the {{{indicationType}}} of {{{indication}}}. Common adverse reactions include .

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Indications

  • Nighttime sleep-aid

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Doxylamine succinate in adult patients.

Non–Guideline-Supported Use

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Doxylamine succinate in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding FDA-Labeled Use of Doxylamine succinate in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Doxylamine succinate in pediatric patients.

Non–Guideline-Supported Use

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Doxylamine succinate in pediatric patients.

Contraindications

  • Condition1

Warnings

Do not give

  • To children under 12 years of age

Ask a doctor before use if you have

  • A breathing problem such as asthma, emphysema or chronic bronchitis
  • Glaucoma
  • Trouble urinating due to an enlarged prostate gland

Ask a doctor or pharmacist before use if you are

  • Taking any other drugs

When using this product

  • Avoid alcoholic beverages
  • Take only at bedtime

Stop use and ask a doctor if

  • Sleeplessness persists continuously for more than two weeks. Insomnia may be a symptom of serious underlying medical illness.

If pregnant or breast-feeding,

  • Ask a health professional before use

Keep out of reach of children

  • In case of overdose, get medical help or contact a Poison Control Center right away.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Doxylamine succinate in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Doxylamine succinate in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Drug Interactions

  • Drug
  • Description

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • Pregnancy Category


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Doxylamine succinate in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Doxylamine succinate during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Doxylamine succinate with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Doxylamine succinate with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Doxylamine succinate with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Doxylamine succinate with respect to specific gender populations.

Race

There is no FDA guidance on the use of Doxylamine succinate with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Doxylamine succinate in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Doxylamine succinate in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Doxylamine succinate in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Doxylamine succinate in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Oral
  • Intravenous

Monitoring

There is limited information regarding Monitoring of Doxylamine succinate in the drug label.

  • Description

IV Compatibility

There is limited information regarding IV Compatibility of Doxylamine succinate in the drug label.

Overdosage

Acute Overdose

Signs and Symptoms

  • Description

Management

  • Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Doxylamine succinate in the drug label.

Pharmacology

There is limited information regarding Doxylamine succinate Pharmacology in the drug label.

Mechanism of Action

Structure

File:Doxylamine succinate01.png
This image is provided by the National Library of Medicine.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Doxylamine succinate in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Doxylamine succinate in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Doxylamine succinate in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Doxylamine succinate in the drug label.

How Supplied

Storage

There is limited information regarding Doxylamine succinate Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Doxylamine succinate |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Doxylamine succinate |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Doxylamine succinate in the drug label.

Precautions with Alcohol

  • Alcohol-Doxylamine succinate interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

Look-Alike Drug Names

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. Empty citation (help)
  2. "http://www.ismp.org". External link in |title= (help)

{{#subobject:

 |Page Name=Doxylamine succinate
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}}
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject:

 |Label Page=Doxylamine succinate
 |Label Name=Doxylamine succinate11.png

}}

{{#subobject:

 |Label Page=Doxylamine succinate
 |Label Name=Doxylamine succinate11.png

}}